Table 2.

NcRNA-based anti-angiogenesis therapies in lung cancer

Therapeutic tools	Type	Targets	Functions	References
Nucleolin aptamer-siRNA chimaeras	siRNA	SLUG and NRP1	Suppress lung cancer cell invasion, tumor growth and angiogenesis	[96]
Bivalent cyclic RGD-siRNA conjugate	siRNA	VEGFR2	Inhibiting neovascularization and proliferation on NSCLC xenografts	[97]
siRNA nanoemulsions	siRNA	CXCR4 and STAT3	Inhibit tumor proliferation and neovascularization in lung metastases	[99]
Global miRNA depletion	Endoribonuclease	FIH1/HIF pathway	Suppress angiogenesis in NSCLC cell line and xenografts	[101]
miR-16/322/497/17	miRNA	VEGFR2	Inhibit tumor angiogenesis in a murine Lewis lung cancer model	[103]
miR-125b	miRNA	VE-cadherin	Inducing nonfunctional blood vessel formation to inhibit tumor growth	[104]
Multi-functional NPs	siRNA	VEGF	Inhibits tumor proliferation and angiogenesis in orthotopic NSCLC	[105]

This table summarizes the research on ncRNA-based anti-angiogenic therapeutics in lung cancer